Quantifying the Impact of Comorbidities on Outcomes Following Surgery for Osteoporotic Vertebral Compression Fractures

Anmol Gupta¹  Thomas Cha¹  Joseph Schwab¹  Harold Fogel¹  Daniel Tobert¹  Afshin E. Razi²
Carl Paulino³  Christopher M. Bono¹  Stuart Hershman¹

¹Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, The Mount Sinai Hospital, Massachusetts General Hospital, Boston, Massachusetts, United States
²Department of Orthopaedics, Maimonides Bone and Joint Center, Maimonides Medical Center, Brooklyn, New York, United States
³Department of Orthopaedic Surgery, SUNY Downstate Health Sciences University, NYP Brooklyn Methodist Hospital, Brooklyn, New York, United States

Address for correspondence Stuart Hershman, MD, Department of Orthopaedics, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States
(e-mail: shershman@mgh.harvard.edu).

Introduction  Studies have shown that osteoporotic patients are more likely to have medical or surgical complications postoperatively. In this study, we determine the predictive value of various comorbidities on the likelihood of postoperative complications, mortality, and 30-day readmission following cement augmentation for osteoporotic vertebral compression fractures (OVCFs).

Materials and Methods  A retrospective analysis of the American College of Surgeons National Surgery Quality Improvement Project (ACS-NSQIP) database from 2007 to 2014 identified 1979 patients who met inclusion criteria. A multivariate logistic regression analysis was utilized to determine the relationship between various comorbidities and perioperative mortality, postoperative complications, and 30-day readmission rates.

Results  A history of cerebrovascular accident (CVA), coagulopathy, diminished preoperative functional status, and/or an American Society of Anesthesiologists (ASA) class > 2 were statistical predictors of postoperative complications. CVA generated the highest odds ratio among these comorbidities (OR = 5.36, \( p = 0.02 \) for minor complications; OR = 4.60, \( p = 0.05 \) for major complications). Among the 15 comorbidities considered, steroid use (OR = 1.81, \( p = 0.03 \)) and an ASA class > 2 (OR = 14.65, \( p = 0.01 \)) were the only ones that were correlated with mortality; an ASA class > 2 had a particularly strong effect on the likelihood of mortality (OR = 14.65). Chronic obstructive pulmonary disorder (COPD), obesity, significant weight loss, and an ASA class > 2 were correlated with 30-day readmissions. Congestive heart failure (CHF), diabetes, dialysis, hypertension, or smoking was not correlated with adverse postoperative outcomes.

Conclusion  Of the 15 comorbidities considered in this study, four were statistically associated with increased rates of postoperative complications, two were associated with increased mortality, and four were associated with increased rates of readmission at 30 days. The presence of CHF, diabetes mellitus (DM), hypertension, ascites, renal failure, or smoking were not associated with the adverse outcomes studied.

Level of Evidence III.

Keywords  ► mortality
► vertebral compression fracture
► osteoporosis
► cement augmentation

Abstract

DOI https://doi.org/10.1055/s-0041-1729466
ISSN 2457-0214
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction
Each year, over two million fragility fractures occur in the United States, hospitalizing over 500,000 elderly patients and costing the health care system over $5.1 billion annually. Among these fragility fractures, roughly one third are osteoporotic vertebral compression fractures (OVCFs). OVCFs commonly cause dysfunction, severe pain, and postural changes that may be treated via cement augmentation procedures. Considering the rising incidence of osteoporotic fractures in the population and the frailty commonly associated with OVCF patients, literature regarding the clinical management of this condition is becoming progressively more relevant. Treatment options for OVCF include benign neglect, bracing, medication, and procedures such as cement augmentation. While the treatment plan for a given patient is based on various clinical factors, several studies have shown that vertebral cement augmentation may offer better long-term pain relief than medical management alone for a subset of patients. However, prior to recommending an invasive procedure, clinicians must consider the risk-profile of each patient. In this study, we attempt to determine the relationship between 15 comorbidities and the likelihood of developing complications, mortality, or 30-day readmission following an invasive procedure for an OVCF. In doing so, we hope to help guide clinical decision-making regarding treatment plans and help clinicians manage patients’ expectations following vertebral cement augmentation.

Materials and Methods
In this retrospective study, data from the American College of Surgeons National Surgery Quality Improvement Project (ACS-NSQIP) from 2007 through 2014 was reviewed. Because information within this database is deidentified, this study was exempt from institutional review board (IRB) approval. Following a methodology utilized by others, patients who sustained an OVCF in the lumbar or thoracic region of the spine were identified using current procedural terminology (CPT) codes and International Classification of Disease (ICD-9 or ICD-10) codes. ICD-9 codes 733.13, 805.2, and 805.4 (utilized for the years 2007–2013) and ICD-10 codes M48.56XA, S22.009A, S22.068A, and S22.089A (used for 2014) were also included in this study. To ensure all target patients in the ACS-NSQIP database were captured, patients assigned any of the following CPT codes were also included: 22510, 22511, 22512, 22513, 22514, or 22515; these CPT codes refer to vertebral cement augmentation procedures.

Patients with an OVCF in the cervical, sacral, or unclassified region of the spine, and/or those with confirmed spinal or central nervous system (CNS) tumors were excluded. For purposes of conducting a logistic regression analysis, the following patient characteristics were considered: gender, body mass index (BMI), functional status prior to procedure, preoperative comorbidities and preoperative serum albumin level, American Society of Anesthesiologists (ASA) status, postoperative complications, mortality, reoperations, and 30-day readmissions. If greater than 10 percent of patients were missing data for a given variable, that variable was excluded from the study.

Outcome measures for this study included minor postoperative complications, major postoperative complications, patient mortality, 30-day readmission due to any cause, and 30-day readmission related to OVCF. As in previous studies by Chung et al., the following issues were considered minor postoperative complications: pneumonia, urinary tract infection (UTI), deep vein thrombosis (DVT), or incision site complications. Major postoperative complications included cardiac arrest, acute myocardial infarction (MI), sepsis, septic shock, stroke, pulmonary embolism (PE), acute renal failure, a coma lasting more than 24 hours, and reintubation.

Statistical Analysis
Using multivariate logistic regression, odds ratios (OR) with corresponding p values and 95% confidence intervals (CI) were calculated. This statistical tool was used to determine the direct correlation between 15 comorbidities and primary outcome measures, while also accounting for possible confounders such as age, gender, or preoperative serum albumin levels. While most comorbidities were considered dichotomous, preoperative functional status was treated as a categorical variable. Patients exhibiting an inability to perform at least one activity of daily living (ADL) were considered partially dependent; if a patient was unable to perform any ADLs, he or she was classified as completely dependent. Preoperative serum albumin level was treated as a continuous variable. To determine which variables should be utilized in the logistic regression, a series of bivariate analyzes between age and the variable in question were conducted; those that generated p values less than 0.05 were included in the multivariate analysis. Any variable for which fewer than five incidences occurred within the patient dataset was excluded. For statistical purposes, a patient listed as greater than 90 years of age in the ACS-NSQIP database was treated as a 90-year-old.

Results
Upon application of inclusion and exclusion criteria, 1979 patients were found in the ACS-NSQIP database. Table 1 provides a demographic overview of our study population. Patients were on average approximately 74 years of age at the time of vertebral cement augmentation. More than two-thirds were female and the average BMI was slightly under 27. Approximately one out of seven patients had a smoking history within 1 year of the index procedure; the same was true regarding chronic steroid use and diminished functional status prior to intervention. On average, patients had a preoperative albumin in the healthy range (> 3.5). Table 2 summarizes the prevalence of various comorbidities as well as the distribution of ASA status in the study population. Nearly two-thirds of patients had a history of hypertension and more than one-quarter were obese; almost 80% of patients had an ASA class of III or higher, highlighting the frailty of OVCF patients. Table 3 summarizes postoperative outcomes in our study population. Mortality
was seen in 4.6% of patients within 30 days of the index procedure, and 13.1% of patients were readmitted. Overall, 5.1% of patients experienced a major complication, most commonly sepsis and reintubation, and 7.2% of patients suffered minor complications.

Table 1  Patient characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Total (n = 1979)</th>
<th>SD or %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) *</td>
<td>73.92</td>
<td>10.82</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>1328</td>
<td>67.1%</td>
</tr>
<tr>
<td>BMI</td>
<td>26.74</td>
<td>6.45</td>
</tr>
<tr>
<td>Mean preoperative albumin</td>
<td>3.58</td>
<td>0.65</td>
</tr>
<tr>
<td>Steroid use for chronic condition</td>
<td>293</td>
<td>14.8%</td>
</tr>
<tr>
<td>Smoking history</td>
<td>270</td>
<td>13.6%</td>
</tr>
<tr>
<td>On dialysis</td>
<td>26</td>
<td>1.3%</td>
</tr>
<tr>
<td>Functional status prior to surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Independent</td>
<td>1661</td>
<td>85.3%</td>
</tr>
<tr>
<td>Partially dependent</td>
<td>265</td>
<td>13.6%</td>
</tr>
<tr>
<td>Totally dependent</td>
<td>22</td>
<td>1.1%</td>
</tr>
<tr>
<td>Unknown</td>
<td>31</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; SD, standard deviation.
\* For statistical purposes, patients age 90+ are assumed to be 90 years of age.

Table 2  Comorbidities and distribution of ASA status across 1979 patients

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th># Patients</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>56</td>
<td>2.8%</td>
</tr>
<tr>
<td>COPD</td>
<td>307</td>
<td>15.5%</td>
</tr>
<tr>
<td>Coagulopathy</td>
<td>173</td>
<td>8.7%</td>
</tr>
<tr>
<td>CVA</td>
<td>16</td>
<td>0.8%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>385</td>
<td>19.5%</td>
</tr>
<tr>
<td>Dialysis</td>
<td>26</td>
<td>1.3%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1317</td>
<td>66.5%</td>
</tr>
<tr>
<td>Ascites</td>
<td>3</td>
<td>0.2%</td>
</tr>
<tr>
<td>MI &lt; 6 months</td>
<td>0</td>
<td>0.0%</td>
</tr>
<tr>
<td>Obesity (BMI ≥ 30)</td>
<td>497</td>
<td>25.1%</td>
</tr>
<tr>
<td>Renal Failure</td>
<td>4</td>
<td>0.2%</td>
</tr>
<tr>
<td>Smoker (w/in last year)</td>
<td>270</td>
<td>13.6%</td>
</tr>
<tr>
<td>Steroid use for chronic condition</td>
<td>293</td>
<td>14.8%</td>
</tr>
<tr>
<td>Weight loss</td>
<td>66</td>
<td>3.3%</td>
</tr>
<tr>
<td>ASA Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA Class I</td>
<td>11</td>
<td>0.6%</td>
</tr>
<tr>
<td>ASA Class II</td>
<td>390</td>
<td>19.7%</td>
</tr>
<tr>
<td>ASA Class III</td>
<td>1297</td>
<td>65.6%</td>
</tr>
<tr>
<td>ASA Class IV</td>
<td>274</td>
<td>13.9%</td>
</tr>
<tr>
<td>ASA Class V</td>
<td>4</td>
<td>0.2%</td>
</tr>
<tr>
<td>None listed</td>
<td>3</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disorder; CVA, cerebrovascular accident; MI, myocardial infarction.

Fig. 1 summarizes the results of our multivariate logistic regression. To determine which factors to integrate into the analysis, a series of bivariate tests were conducted. Of the 15 comorbidities recorded in our database, 11 bore a statistical impact (p value < 0.05) on at least one of the primary outcome measures. These included a history of congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), coagulopathy, cerebrovascular accident (CVA), diabetes mellitus (DM), dialysis, obesity, long-term steroid use, weight loss exceeding 10% of body weight over the past 6 months, ASA class > 2, and preoperative functional status. Ascites and renal failure had fewer than five incidences and therefore were excluded from analysis. In addition, hypertension and smoking were also excluded from the analysis because the bivariate analyses for these variables failed to demonstrate statistical significance. To further validate our results, age, gender, and preoperative serum albumin levels were also integrated in our analysis.

Results from Fig. 1 show that preoperative functional status (p = 0.03 and 0.05), ASA class > 2 (p = 0.01), and/or a history of CVA (p = 0.02) were statistically correlated with minor complications. Preoperative functional status (p < .01).
Impact of Comorbidities on Outcomes Following Surgery for Osteoporotic Vertebral Compression Fractures

Gupta et al.

As a result of the high prevalence of OVCF is estimated to be 25% in postmenopausal women over age 50, and 40% of women over age 80, thus making the management of OVCF highly relevant to patient care and health care costs. As a result of the high prevalence, demographics, interventions, and patient outcomes following procedures for OVCF have been well-studied.

Discussion

As the most common type of fragility fracture, OVCFs occur every 22 seconds on average around the globe. The prevalence of OVCF is estimated to be 25% in postmenopausal women over age 50, and 40% of women over age 80, thus making the management of OVCF highly relevant to patient care and health care costs.

To explain this, we considered the long-term treatment of CVA, which commonly involves antiplatelet or anticoagulant therapy to prevent reoccurrence. Prior to intervention, CVA patients often discontinue their anticoagulation medication.

While we found that patient ASA class was associated with complications, we also identified correlations with a history of CVA and coagulopathy. These comorbidities are, not surprisingly, among those factors that would lead to an ASA classification greater than 2. At the same time, other comorbidities that may also place patients in the same category, such as CHF or hypertension, were not found to be associated with any adverse outcomes following cement augmentation for OVCF. By providing this specific quantitative data from a large sample size, we hope to identify which comorbidities predict complications, mortality, or readmission, potentially enabling physicians to form a better treatment plan.

Our data shows that the most significant predictor of complications, both in terms of statistical significance and OR, is a history of CVA (p = 0.02 and OR = 5.36 for minor complications; p = 0.05 and OR = 4.60 for major complications). Coagulopathy was also associated with major postoperative complications (p = 0.03 and OR = 1.89), however neither coagulopathy nor a history of CVA was found to be statistically correlated with mortality or readmission.

Our theory is supported by the literature, which suggests that 25% of CVA are recurrent, thereby increasing the likelihood of such an event in patients with a history of CVA.

In terms of mortality, we found a statistical association in patients using steroids and those with ASA status > 2. This correlation may be due to the association of steroids with sepsis and septic shock. While these complications are somewhat rare (1.9% experienced sepsis and 0.9% endured septic shock), they are often life-threatening in the frail and elderly OVCF population. In one study relating to colorectal surgery, patients using steroids chronically were shown...
Impact of Comorbidities on Outcomes Following Surgery for Osteoporotic Vertebral Compression Fractures

Gupta et al.

The ACS-NSQIP database utilized in this study enabled us to analyze postprocedural outcomes following cement augmentation for the treatment of OVCF. However, we are unable to comment on how patients who are treated nonsurgically do in comparison to those who undergo cement augmentation based on our data. To address this alternative approach, we consider recent literature. Ong et al, in a 5-year study, showed that both balloon kyphoplasty and vertebroplasty were associated with statistically lower mortality rates in comparison to nonsurgical management of vertebral compression fractures. Similarly, Hirsch et al utilized a 10-year sample of Medicare data to conduct a number needed to treat analysis. This study showed that at both 1-year and 5-year follow-ups kyphoplasty patients did better. The adjusted number needed to treat to save 1 life from nonsurgical management versus kyphoplasty was 14.8 at year 1 and 11.9 at year 5. Finally, Hinde et al, in a 2020 systematic review involving over two million patients, showed that patients who underwent vertebral augmentation procedures for treatment of OVCF were 22% less likely to expire 10 years postintervention. Thus, while some patients undergo complications from vertebral augmentation, for most people suffering from OVCF, it remains a stronger alternative to nonoperative management.

This study has multiple limitations. Our findings depend on the accuracy of deidentified spreadsheets from the ACS-NSQIP database without the possibility of verification through viewing original patient charts. Therefore, it is possible that patients may have been improperly included or excluded due to potential errors within the ACS-NSQIP database. While the NSQIP database is frequently utilized, there was no obvious way to correct for this. Furthermore, the NSQIP database does not provide information with regard to the specialty of the treating physician; it is possible that the outcomes of augmentation procedures conducted by interventional radiologists differ from those performed by surgeons or other subspecialists. It also is unable to provide information regarding adherence (or lack thereof) by clinicians to standardized care pathways such as SIR, SNIS, or the UCLA/Rand appropriateness method. These guidelines help ensure the standard of care is followed when treating patients.

From a more technical perspective, another challenge with the NSQIP database is its use of the term “null” instead of “no” when identifying patients with CNS tumors. While both terms are used throughout the database, the former term, in comparison to the latter, does not provide the same degree of certainty that a patient does not have a CNS tumor. In this study, both terms were considered acceptable for purposes of meeting inclusion criteria. Finally, variables recorded in ACS-NSQIP changed from year to year; periodically, some were added while others were removed. Although this constraint was carefully tracked and accounted for, it necessitated the exclusion of some variables from our regression analysis. Our analysis of 30-day readmission rates is also limited by the database. ACS-NSQIP defines a 30-day readmission from the date of the procedure and not the date of discharge. Therefore, a sick patient discharged 3 weeks after the index procedure has only 9 days postdischarge to qualify for a 30-day readmission using this methodology. On the contrary, a patient discharged 2 days following an uncomplicated procedure has 28 days to be readmitted to be considered a 30-day readmission. This record-keeping limitation may have impacted our ability to fully assess the relationship between 30-day readmission and the comorbidities considered. Moreover, ACS-NSQIP does not track readmissions that occur after the initial 30-day period following a procedure.

Other limitations include the decision to avoid distinguishing between different procedural modalities. This study did not control for whether a patient underwent a multilevel or a single-level procedure in treating an OVCF. It also did not distinguish between cement augmentation techniques. In this database study, we relied on the clinical judgment of the clinician to identify which procedure would be best for a...
given patient, without controlling for the modality utilized. Future studies could compare other factors that may be statistically associated with adverse outcomes in the setting of OVF, such as inpatient status prior to procedure or postoperative disposition. It may also be valuable to investigate the correlation between the factors considered in this study and other spine pathologies.

**Conclusion**

Data from this study may help clinicians identify comorbidities that can significantly affect outcomes. By quantifying the risk associated with these comorbidities, clinicians may be better equipped to guide the expectations of their patients and form treatment plans. Of the 15 comorbidities considered in this study, four were statistically associated with complications (preoperative functional status; ASA class > 2; history of coagulopathy; history of CVA), two were associated with increased rates of mortality (chronic steroid use; ASA class > 2), and four were associated with increased rates of readmission (COPD; obesity; weight loss; ASA class > 2). A history of CHF, DM, hypertension, ascites, renal failure, and smoking were not found to be associated with these adverse outcomes.

**Note**

The manuscript submitted does not contain information about medical device(s)/drug(s). No funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript. This study is exempt from IRB approval, as it utilizes data from the deidentified ACS-NSQIP database.

**Conflict of Interest**

None declared

**References**

27 Guzik A, Bushnell C. Stroke epidemiology and risk factor management. Continuum (Minneap Minn) 2017;23(1, Cerebrovascular Disease): 15–39
41 Ong KI, Beall DP, Frohbergh M, Lau E, Hirsch JA. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? Osteopor Int 2018;29(2):375–383